Cited by 830Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, Lecia V., Martins, Renato G., Spigel, David, Grunberg, Steven M., Spira, Alexander, Jänne, Pasi A., Joshi, Victoria A., McCollum, David, Evans, Tracey L., Muzikansky, Alona, Kuhlmann, Georgiana L., Han, Moon, Goldberg, Jonathan S., Settleman, Jeffrey, Iafrate, A. John, Engelman, Jeffrey A., Haber, Daniel A., Johnson, Bruce E., Lynch, Thomas J.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.8494

Open this paper in CoChat — free account

Abstract

PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms. PATIENTS AND METHODS: Chemotherapy-naïve patients with advanced NSCLC with >or= 1 clinical characteristic associated with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21. Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity. The primary outcome was response rate. RESULTS: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%). EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21% of mutation-positive cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q. Thirty-one patients received gefitinib. The response rate was 55% (95% CI, 33 to 70) and median progression-free survival was 9.2 months (95% CI, 6.2 to 11.8). Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis. Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification. CONCLUSION: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance. This strategy should be compared with combination chemotherapy, the current standard of care.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.8494

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citation
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citation

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 401–500 of 830

Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer
Laack, E., Sauter, G., & Bokemeyer, C. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.05.015 · Cited by 28
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
Deng, Q., Xie, B., Wu, L., Ji, X., Li, C., Li, F., Fang, Q., Bao, Y., Li, J., Jin, S., et al. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e01031 · Cited by 27
Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study
Yu, S. (2012) · Oncology Letters · doi:10.3892/ol.2012.585 · Cited by 27
Roles of circRNAs in cancer chemoresistance (Review)
Xin, C., Huang, F., Wang, J., Li, J., & Chen, Q. (2021) · Oncology Reports · doi:10.3892/or.2021.8176 · Cited by 27
Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues
Christoffersen, T., Guren, T. K., Spindler, K. G., Dahl, O., Lønning, P. E., & Gjertsen, B. T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.009 · Cited by 26
Capturing a novel metastable polymorph of the anticancer drug gefitinib
Thorat, S. H., Patwadkar, M. V., Gonnade, R. G., & Vaidhyanathan, R. (2014) · CrystEngComm · doi:10.1039/c4ce01446d · Cited by 27
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
Tan, E.-H., Lim, W., Ahn, M., Ng, Q., Ahn, J. S., Tan, D. S., Sun, J., Han, M., Payumo, F. C., McKee, K., et al. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.427 · Cited by 27
Self-citation
Down-regulation of FOXR2 inhibits non-small cell lung cancer cell proliferation and invasion through the Wnt/β-catenin signaling pathway
Wang, X., Cui, Y., Wang, Z.-M., & Liu, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.046 · Cited by 27
Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors
Ouyang, Y., Zou, W., Liang, P., Yang, Z., Tang, Q., Chen, M., Jia, S., Zhang, H., Zhou, L., Zheng, P., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.05.006 · Cited by 27
Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
Romero, A., Lewintre, E. J., García‐Peláez, B., Royuela, A., Insa, A., Cruz, P., Collazo-Lorduy, A., Altozano, J. P., Juan, Ó., Díz, P., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12832 · Cited by 27
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Bonanno, L., Jirillo, A., & Favaretto, A. G. (2011) · Current Drug Targets · doi:10.2174/138945011795528958 · Cited by 27
EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas
Basu, D., Bewley, A. F., Sperry, S. M., Montone, K. T., Gimotty, P. A., Räsänen, K., Facompre, N. D., Weinstein, G. S., Nakagawa, H., Diehl, J. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1210 · Cited by 26
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment
Yang, C., Chong, I., Tsai, M., Hung, J., Chou, S., Lee, J., Hsu, J., Tsai, Y., Liu, T., & Huang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100164 · Cited by 26
High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation
Tian, P., Wang, Y., Wang, W., Li, Y., Wang, K., Cheng, X., Tang, Y., Han‐Zhang, H., Ye, J., Chuai, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.014 · Cited by 25
Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography
Iommelli, F., Rosa, V. D., Gargiulo, S., Panico, M., Monti, M., Greco, A., Gramanzini, M., Ortosecco, G., Fonti, R., Brunetti, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0264 · Cited by 26
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
Kim, I. A., Lee, J. S., Kim, H. J., Kim, W. S., & Lee, K. Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4691-0 · Cited by 25
Targeted therapy: An evolving world of lung cancer
Lam, K. C., & Mok, T. S. K. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01821.x · Cited by 25
Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
Mansuet‐Lupo, A., Zouiti, F., Alifano, M., Tallet, A., Charpentier, M.-C., Ducruit, V., Devez, F., Lemaitre, F., Laurent‐Puig, P., Damotte, D., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-131 · Cited by 25
Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma
Li, Y., Li, W., He, Q., Xu, Y.-F., Ren, X., Tang, X.-R., Wen, X., Yang, X.-J., Sun, Y. H., Zeng, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3751 · Cited by 25
Subsequent Treatment Choices for Patients with Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer: Restore after a Drug Holiday or Switch to another EGFR-TKI?
Song, T., Yu, W., & Wu, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.1.205 · Cited by 25
High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer
Bondgaard, A.-L., Høgdall, E. V. S., Mellemgaard, A., & Skov, B. G. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.67 · Cited by 25
Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities
Krajewski, K. M., Braschi‐Amirfarzan, M., DiPiro, P. J., Jagannathan, J. P., & Shinagare, A. B. (2017) · Korean Journal of Radiology · doi:10.3348/kjr.2017.18.1.28 · Cited by 28
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy
Ghafoor, Q., Baijal, S., Taniere, P., O’Sullivan, B., Evans, M., & Middleton, G. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0377-1 · Cited by 25
Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach
Goto, T., Hirotsu, Y., Amemiya, K., Mochizuki, H., & Omata, M. (2018) · Cancers · doi:10.3390/cancers10070212 · Cited by 25
Gefitinib for the treatment of non-small-cell lung cancer
Campbell, L., Blackhall, F. H., & Thatcher, N. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.481283 · Cited by 25
Clinical Outcomes in Non-Small-Cell Lung Cancer in Relation to Expression of Predictive and Prognostic Biomarkers
Singh, N., Bal, A., Aggarwal, A. N., Das, A., & Behera, D. (2010) · Future Oncology · doi:10.2217/fon.10.30 · Cited by 24
Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
Sun, J., Ahn, M., Park, M. J., Yi, J. H., Kim, T. S., Chung, M. J., Park, Y. H., Ahn, J. S., & Park, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.09.014 · Cited by 24
Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study
Gu, J., Zang, W., Liu, B., Li, L., Huang, L., Li, S., Rao, G., Yu, Y., & Zhou, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18866 · Cited by 24
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature
Albaba, H., Lim, C. H., & Leighl, N. B. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0563-8 · Cited by 24
Irreversible EGFR-TKIs: dreaming perfection.
Landi, L. M., & Cappuzzo, F. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.05 · Cited by 25
Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation
Jiao, S., Peng, L., & Song, Z. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s78984 · Cited by 24
Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer
Arvold, N. D., Heidari, P., Kunawudhi, A., Sequist, L. V. D., & Mahmood, U. (2015) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615574386 · Cited by 23
Self-citation
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
Reguart, N. (2010) · Cancer Management and Research · doi:10.2147/cmar.s5398 · Cited by 23
Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer
Losanno, T., & Gridelli, C. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1170116 · Cited by 23
MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity
Sakai, A., Kasahara, K., Ohmori, T., Kimura, H., Sone, T., Fujimura, M., & Nakao, S. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825cca4c · Cited by 22
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
Martínez‐Martí, A., Navarro, A., & Felip, E. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.20 · Cited by 22
Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma
Yang, C., Chen, W., Gong, G., Li, Z., Qiu, Q., & Yin, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1216 · Cited by 22
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
Schöttle, J., Chatterjee, S., Volz, C., Siobal, M., Florin, A., Rokitta, D., Hinze, Y., Dietlein, F., Plenker, D., König, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6276 · Cited by 22
Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib
Ali, S. M., Alpaugh, R. K., Buell, J. K., Stephens, P. J., Yu, J. Q., Wu, H., Hiemstra, C. N., Miller, V. A., Lipson, D., Palmer, G. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.09.010 · Cited by 22
First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation; Positive Non-small Cell Lung Cancer Patients
Sequist, L. V. D. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e981 · Cited by 22
Self-citation
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
Lee, Y. J., Kim, H. T., Han, J., Yun, T., Lee, G. K., Kim, H. Y., Sung, J.-H., & Lee, J. S. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181cee1ea · Cited by 22
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma
Leng, X., Wei, S., Mei, J., Deng, S., Yang, Z., Liu, Z., Guo, C., Deng, Y., Xia, L. P., Cheng, J., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-146 · Cited by 22
KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas
Dahse, R., Driemel, O., Schwarz, S., Kromeyer-Hauschild, K., Berndt, A., & Kosmehl, H. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.01.013 · Cited by 22
Gefitinib in the treatment of advanced non-small-cell lung cancer
Reck, M. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.1 · Cited by 22
Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas
Wu, Z., Bai, F., Fan, L., Pang, W., Han, R., Wang, J., Liu, Y., Xia, Y., Duan, H., & Xing, L. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.08.014 · Cited by 21
Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment
Okamoto, I., Yoshida, & Kaneda (2013) · Cancer Management and Research · doi:10.2147/cmar.s32973 · Cited by 21
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
Koopman, B., Garcia, B. N. C., Kuijpers, C. C. H. J., Damhuis, R. A. M., van der Wekken, A. J., Groen, H. J. M., Schuuring, E. M. D., Willems, S. M., & van Kempen, L. C. L. T. (2021) · Cancers · doi:10.3390/cancers13143641 · Cited by 22
Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
Huang, C., Ju, J., Chiu, T.-H., Huang, A. C., Tung, P., Wang, C., Liu, C., Chung, F., Fang, Y., Guo, Y., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33821 · Cited by 21
Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer
Peled, N., Yoshida, K., Wynes, M. W., & Hirsch, F. R. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009347923 · Cited by 21
Tyrosine kinase-independent actions of DDR2 in tumor cells and cancer-associated fibroblasts influence tumor invasion, migration and metastasis
Barcus, C. E., Hwang, P. Y., Morikis, V. A., Brenot, A., Pence, P., Clarke, M., & Longmore, G. D. (2021) · Journal of Cell Science · doi:10.1242/jcs.258431 · Cited by 21
Management of Patients with Advanced Non-Small Cell Lung Cancer
Triano, L. R., Deshpande, H. A., & Gettinger, S. N. (2010) · Drugs · doi:10.2165/11532200-000000000-00000 · Cited by 21
Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
Hashida, S., Yamamoto, H., Shien, K., OHTSUKA, T., Suzawa, K., Maki, Y., Furukawa, M., Soh, J., Asano, H., Tsukuda, K., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.3735 · Cited by 21
Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development
Mahalingam, D., Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.03.001 · Cited by 21
Biology of Non–Small Cell Lung Cancer
Massion, P. P., & Carbone, D. P. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00045-6 · Cited by 21
Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
Kobayashi, K., & Tan, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044126 · Cited by 22
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19
Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR
Han, S.-Y., Ding, H.-R., Zhao, W., Teng, F., & Li, P. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-165 · Cited by 20
Epidermal Growth Factor Receptor Signaling in Nonsmall Cell Lung Cancer
Ganti, A. K. (2010) · Cancer Investigation · doi:10.3109/07357900903476760 · Cited by 20
The Emerging Role of Biomarkers in Advanced Non–Small-Cell Lung Cancer
Socinski, M. A. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.019 · Cited by 20
Cell Culture Modeling of Genotype-Directed Sensitivity to Selective Kinase Inhibitors: Targeting the Anaplastic Lymphoma Kinase (ALK)
Settleman, J. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.02.006 · Cited by 20
Self-citation
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
Beau‐Faller, M., Pencreach, E., Leduc, C., Blons, H., Merlio, J., Bringuier, P., de Fraipont, F., Escande, F., Lemoine, A., Ouafik, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.013 · Cited by 21
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
Floros, K. V., Jacob, S., Kurupi, R., Fairchild, C. K., Hu, B., Puchalapalli, M., Koblinski, J. E., Dozmorov, M. G., Boikos, S. A., Scaltriti, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03457-6 · Cited by 20
EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer
Kamel‐Reid, S., Chong, G., Ionescu, D. N., Magliocco, A. M., Spatz, A., Tsao, M., Weng, X., Young, S. S., Zhang, T., & Soulières, D. (2012) · Current Oncology · doi:10.3747/co.19.862 · Cited by 18
Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis
Lee, C. C., Soon, Y. Y., Tan, C. L., Koh, W. Y., Leong, C. N., Tey, J. C. S., & Tham, I. W. K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218414 · Cited by 20
The search for improved systemic therapy of non-small cell lung cancer—What are today's options?
Früh, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.020 · Cited by 20
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
Martin, P., Shiau, C. J., Pasic, M. D., Tsao, M., Kamel‐Reid, S., Lin, S., Tudor, R., Cheng, S. Y.-S., Higgins, B. P., Burkes, R. L., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.22 · Cited by 19
Protein kinase C-iota-mediated glycolysis promotes non-small-cell lung cancer progression
Liu, L., Lei, B., Wang, L., Chang, C., Yang, H., Liu, J., Huang, G., & Xie, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s207211 · Cited by 19
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
Sehgal, K., Rangachari, D., VanderLaan, P. A., Kobayashi, S. S., & Costa, D. B. (2020) · The Oncologist · doi:10.1002/onco.13537 · Cited by 18
Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients
Hashida, S., Soh, J., Toyooka, S., Tanaka, T., Furukawa, M., Shien, K., Yamamoto, H., Asano, H., Tsukuda, K., Hagiwara, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3197 · Cited by 19
High-throughput Screening Identifies Aclacinomycin as a Radiosensitizer of EGFR-Mutant Non-Small Cell Lung Cancer
Bennett, D. C., Charest, J., Sebolt, K. A., Lehrman, M. A., Rehemtulla, A., & Contessa, J. N. (2013) · Translational Oncology · doi:10.1593/tlo.13232 · Cited by 19
A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor
Zhao, J., FENG, H.-H., Zhao, J., LIU, L.-C., Xie, F., Xu, Y., CHEN, M.-J., Zhong, W., Longyun, L. I., WANG, H.-P., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4263 · Cited by 18
Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer
Huang, K., & Liu, D. (2016) · Tumor Biology · doi:10.1007/s13277-015-4689-z · Cited by 18
Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics
Ma, L., Zou, B., & Yan, H. (2016) · Proteome Science · doi:10.1186/s12953-016-0102-0 · Cited by 18
Neoadjuvant Erlotinib and Surgical Resection of a Stage IIIA Papillary Adenocarcinoma of the Lung with an L861Q Activating EGFR Mutation
Ong, M., Kwan, K. F., Kamel‐Reid, S., & Vincent, M. D. (2012) · Current Oncology · doi:10.3747/co.19.908 · Cited by 18
Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?
Pan, S., Xia, W., Ding, Q., Shu, Y., Xu, T., Geng, Y., Lu, Y., Chen, D., Xu, J., Wang, F., et al. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.11.022 · Cited by 18
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib
Donovan, M. J., Kotsianti, A., Bayer‐Zubek, V., Verbel, D., Teverovskiy, M., Cordon‐Cardo, C., Costa, J. C., Greco, F. A., Hainsworth, J. D., & Parums, D. V. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.004 · Cited by 18
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR
Watanabe, M., Kawaguchi, T., Isa, S., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.06.003 · Cited by 18
Toward Noninvasive Genomic Screening of Lung Cancer Patients
Sequist, L. V. D., Engelman, J. A., & Lynch, T. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4875 · Cited by 18
Self-citation
Preclinical Pharmacokinetics and In Vitro Metabolism of BMS-690514, a Potent Inhibitor of EGFR and VEGFR2
Marathe, P., Tang, Y., Sleczka, B. G., Rodrigues, D., Gavai, A. V., Wong, T., Christopher, L. J., & Zhang, H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22099 · Cited by 17
Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non–Small-Cell Lung Cancer: Implications for Personalized Medicine
Murgu, S. D., & Colt, H. G. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.002 · Cited by 17
Customized chemotherapy based on epidermal growth factor receptormutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
Fujita, S., Katakami, N., Masago, K., Yoshioka, H., Tomii, K., Kaneda, T., Hirabayashi, M., Kunimasa, K., Morizane, T., & Mio, T. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-185 · Cited by 17
Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer
Yuan, Y., Li, X., Chen, J., Dong, Weng, S., & Huang, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s34124 · Cited by 17
Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy
Moreira-Leite, F. F., Harrison, L., Mironov, A., Roberts, R. A., & Dive, C. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d95d93 · Cited by 17
Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer
Plönes, T., Engel-Riedel, W., Stoelben, E., Limmroth, C., Schildgen, O., & Schildgen, V. (2016) · Journal of Personalized Medicine · doi:10.3390/jpm6010003 · Cited by 17
Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
Haven, B., Heilig, E., Donham, C., Settles, M., Vasilevsky, N., Owen, K. A., & Reproducibility Project: Cancer Biology (2016) · eLife · doi:10.7554/elife.09462 · Cited by 16
Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancer
Jin, S., Fang, W., Liu, X., Xing, S., Zhan, J., Ma, Y., Huang, Y., Zhou, N., Zhao, H., & Zhang, L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s112158 · Cited by 17
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Neal, J. W., & Sequist, L. V. D. (2010) · PubMed · Cited by 17
Self-citation
Treatment sequences in EGFR mutant advanced NSCLC
Wespiser, M., Swalduz, A., & Pérol, M. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107895 · Cited by 16
Parameters for individualizing systemic therapy in non-small cell lung cancer
Gadgeel, S. M., Coté, M. L., Schwartz, A. G., Matherly, L. H., Wozniak, A. J., & Bepler, G. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.10.001 · Cited by 17
Impact of biomarkers on non-small cell lung cancer treatment
Toschi, L., & Cappuzzo, F. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0132-y · Cited by 16
A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis
Li, J., Chen, P., Wu, Q., Guo, L., Leong, K. W., Chan, K. I., & Kwok, H. F. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04647-x · Cited by 16
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model
Martin, P., Stewart, E., Pham, N., Mascaux, C., Panchal, D., Li, M., Kim, L., Sakashita, S., Wang, D. Y. Q., Sykes, J. R., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.01.002 · Cited by 16
Modern Drug Discovery and Development
Salazar, D. E., & Gormley, G. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00041-7 · Cited by 16
EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts
Lavdovskaia, E. D., Iyevleva, A. G., Соколенко, А. П., Mitiushkina, N. V., Преображенская, Е. В., Tiurin, V. I., Ivantsov, A. O., Валерьевич, Б. И., Stelmakh, L. V., Moiseenko, F. V., et al. (2018) · Oncology Research and Treatment · doi:10.1159/000491441 · Cited by 17
18F‑FDG PET/CT SUVmax and serum CEA levels as predictors for EGFR mutation state in Chinese patients with non‑small cell lung cancer
Gao, X., Wei, C., Zhang, R., Cai, Q., He, Y., Tong, F., Dong, J.-H., Wu, G., & Dong, X. (2020) · Oncology Letters · doi:10.3892/ol.2020.11922 · Cited by 17
Comprehensive Analysis of the Function, Immune Profiles, and Clinical Implication of m1A Regulators in Lung Adenocarcinoma
Bao, G., Li, T. X., Guan, X., Yao, Y., Liang, J., Xiang, Y., & Zhong, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882292 · Cited by 15
First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
Liao, B.-C., Lin, C., & Yang, J. C. (2013) · Drugs · doi:10.1007/s40265-013-0020-8 · Cited by 16
Neoadjuvant Paradigm for Accelerated Drug Development: An Ideal Model in Bladder Cancer
Chism, D. D., Woods, M. E., & Milowsky, M. I. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0023 · Cited by 15
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Yin, Y., Geng, Y., Shao, Y., Hu, X., Li, W., Shu, Y., & Wang, Z.-X. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-126 · Cited by 15
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
Jain, R., & Chen, H. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s126507 · Cited by 15

Authors: Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., & Lynch, T. J.
Affiliations: Brigham and Women's Hospital (US)
From the Massachusetts General Hospital Cancer Center; Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital; Department of Pathology, Massachusetts General Hospital; Department of Biostatistics, Massachusetts General Hospital, Boston; Harvard Medical School/Partners Health Care Center for Genetics and Genomics, Cambridge, MA; University of Washington, Seattle, WA; Sarah Cannon Research Institute, Nashville, TN; Fletcher Allen Health Care, Burlington, VT; Fairfax-Northern...
ORCID: Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Spira, Alexander
Evans, Tracey L.
Muzikansky, Alona
Han, Moon
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2442-2449
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.8494
OpenAlex: W2101329867
Cited by: 820
References: 46
Citations by year: 2026: 4 · 2025: 14 · 2024: 9 · 2023: 11 · 2022: 20 · 2021: 22 · 2020: 34 · 2019: 29 · 2018: 51 · 2017: 51 · 2016: 54 · 2015: 57 · 2014: 68 · 2013: 69 · 2012: 60
FWCI: 81.10
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, non-small cell lung cancer, EGFR mutation, first-line therapy, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, T790M mutation, MET amplification, progression-free survival, response rate, pneumonitis, genotype-directed therapy
MeSH terms: Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prospective Studies, Quinazolines, Survival Rate, Central Nervous System Neoplasms, Treatment Outcome, In Situ Hybridization, Fluorescence, Carcinoma, Large Cell, Disease-Free Survival, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks